Last reviewed · How we verify
Centro Ortopedico y Quirurgico del Pie — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| propanolol | propanolol | marketed | Other | |||
| Triclosan 0.5 % Topical Solution | Triclosan 0.5 % Topical Solution | marketed | ||||
| Hand antisepsis with Propanolol- 1 60%. | Hand antisepsis with Propanolol- 1 60%. | marketed | Infection Control / Antisepsis (non-standard indication) |
Therapeutic area mix
- Infection Control / Antisepsis (non-standard indication) · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Centro Ortopedico y Quirurgico del Pie:
- Centro Ortopedico y Quirurgico del Pie pipeline updates — RSS
- Centro Ortopedico y Quirurgico del Pie pipeline updates — Atom
- Centro Ortopedico y Quirurgico del Pie pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centro Ortopedico y Quirurgico del Pie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centro-ortopedico-y-quirurgico-del-pie. Accessed 2026-05-17.